Related Experiment Video

Updated: Jul 9, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma

Chih-Kwang Sung1, Bryan Choi, Georges Wanna

  • 1Department of Otolaryngology-Head and Neck Surgery, Mount Sinai School of Medicine, New York, New York 10029, USA.

The Laryngoscope
|November 29, 2007
PubMed
Abstract

Insights

Combining oncolytic vesicular stomatitis virus (VSV) with cisplatin showed enhanced squamous cell carcinoma (SCC) tumor cell kill in vitro. In vivo, combination therapy improved rVSV-F efficacy but reduced rVSV-IL12 activity against SCC tumors.

Area of Science:

  • Oncolytic virotherapy
  • Cancer immunotherapy
  • Squamous cell carcinoma research

Background:

  • Vesicular stomatitis virus (VSV) exhibits oncolytic properties, selectively targeting tumor cells.
  • Recombinant VSV vectors, rVSV-F and rVSV-IL12, previously showed antitumor effects against squamous cell carcinoma (SCC).
  • Cisplatin is a standard chemotherapeutic agent for SCC.

Purpose of the Study:

  • To evaluate the efficacy of combining cisplatin with rVSV-F and rVSV-IL12 for SCC treatment.
  • To assess the impact of combination therapy on viral replication, tumor cell survival, tumor control, and animal survival.

Main Methods:

  • In vitro studies involved testing rVSV-F and rVSV-IL12 with cisplatin on SCC cell lines, monitoring viral replication and cell viability.
  • In vivo studies utilized an orthotopic murine SCC model, administering intratumoral virus injections combined with systemic cisplatin.
  • Tumor control and animal survival were assessed in the in vivo model.

Main Results:

  • In vitro, the combination of VSV and cisplatin enhanced tumor cell killing without affecting normal human keratinocytes.
  • In vivo, combination therapy with rVSV-F and cisplatin reduced tumor burden and improved survival compared to controls.
  • However, rVSV-IL12 monotherapy demonstrated superior tumor control and survival rates compared to the combination therapy in vivo.

Conclusions:

  • Cisplatin addition did not impede VSV replication or SCC cell killing in vitro.
  • Combination therapy augmented rVSV-F antitumor activity but diminished rVSV-IL12 efficacy in vivo.
  • Further development of viral vectors and combination strategies may offer improved SCC treatments.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...